Hikma Drug Patent Portfolio

Hikma owns 5 orange book drugs protected by 16 US patents with Levothyroxine Sodium having the least patent protection, holding only 1 patent. And Kloxxado with maximum patent protection, holding 5 patents. Given below is the list of Hikma's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11213480 Phenylephrine hydrochloride ready-to-use solution 26 Sep, 2036
Active
US11471400 Phenylephrine hydrochloride ready-to-use solution 05 Aug, 2036
Active
US11154498 Stabilized liquid formulation of levothyroxine 20 Jul, 2036
Active
US11213498 Aqueous formulation comprising paracetamol and ibuprofen 14 Jan, 2036
Active
US11389416 Aqueous formulation comprising paracetamol and ibuprofen 17 Jul, 2035
Active
US12083087 Aqueous formulation comprising paracetamol and ibuprofen 17 Jul, 2035
Active
US10722510 Liquid naloxone spray 26 Aug, 2034
Active
US10973814 Liquid naloxone spray 26 Aug, 2034
Active
US11135155 Liquid naloxone spray 26 Aug, 2034
Active
US11617713 Liquid naloxone spray 26 Aug, 2034
Active
US11628139 Liquid naloxone spray 26 Aug, 2034
Active
US11446266 Combination composition 26 Oct, 2031
Active
US11896567 Combination composition 26 Oct, 2031
Active
US6451289 Albuterol formulations 21 Mar, 2021 Expired
US5547994 Method for treating asthma using optically pure R(-) albuterol 20 Aug, 2013 Expired
US5362755 Method for treating asthma using optically pure (R)-albuterol 25 Mar, 2013 Expired


Given below is the list of recent legal activities going on the following drug patents of Hikma.

Activity Date Patent Number
Patent litigations
Mail Patent eGrant Notification 13 Feb, 2024 US11896567
Patent Issue Date Used in PTA Calculation 13 Feb, 2024 US11896567
Recordation of Patent eGrant 13 Feb, 2024 US11896567
Recordation of Patent Grant Mailed 13 Feb, 2024 US11896567
Email Notification 13 Feb, 2024 US11896567
Patent eGrant Notification 13 Feb, 2024 US11896567
Email Notification 25 Jan, 2024 US11896567
Issue Notification Mailed 24 Jan, 2024 US11896567
Payment of Maintenance Fee, 4th Year, Large Entity 23 Jan, 2024 US10722510
Dispatch to FDC 16 Jan, 2024 US11896567
Application Is Considered Ready for Issue 16 Jan, 2024 US11896567
Issue Fee Payment Received 05 Jan, 2024 US11896567
Issue Fee Payment Verified 05 Jan, 2024 US11896567
Email Notification 11 Oct, 2023 US11896567
Mail Miscellaneous Communication to Applicant 11 Oct, 2023 US11896567


Hikma's Family Patents

Hikma drugs have patent protection in a total of 9 countries. It has a significant patent presence in the US with 62.5% of its patents being US patents. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree.

Family Patents



Hikma Drug List

Given below is the complete list of Hikma's drugs and the patents protecting them.


1. Combogesic Iv

Combogesic Iv is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11213498 Aqueous formulation comprising paracetamol and ibuprofen 14 Jan, 2036
(11 years from now)
Active
US11389416 Aqueous formulation comprising paracetamol and ibuprofen 17 Jul, 2035
(10 years from now)
Active
US12083087 Aqueous formulation comprising paracetamol and ibuprofen 17 Jul, 2035
(10 years from now)
Active
US11446266 Combination composition 26 Oct, 2031
(7 years from now)
Active
US11896567 Combination composition 26 Oct, 2031
(7 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Combogesic Iv's drug page


2. Immphentiv

Immphentiv is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11213480 Phenylephrine hydrochloride ready-to-use solution 26 Sep, 2036
(11 years from now)
Active
US11471400 Phenylephrine hydrochloride ready-to-use solution 05 Aug, 2036
(11 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Immphentiv's drug page


3. Kloxxado

Kloxxado is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10722510 Liquid naloxone spray 26 Aug, 2034
(9 years from now)
Active
US10973814 Liquid naloxone spray 26 Aug, 2034
(9 years from now)
Active
US11135155 Liquid naloxone spray 26 Aug, 2034
(9 years from now)
Active
US11617713 Liquid naloxone spray 26 Aug, 2034
(9 years from now)
Active
US11628139 Liquid naloxone spray 26 Aug, 2034
(9 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kloxxado's drug page


4. Levothyroxine Sodium

Levothyroxine Sodium is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11154498 Stabilized liquid formulation of levothyroxine 20 Jul, 2036
(11 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Levothyroxine Sodium's drug page


5. Xopenex

Xopenex is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6451289 Albuterol formulations 21 Mar, 2021
(3 years ago)
Expired
US5547994 Method for treating asthma using optically pure R(-) albuterol 20 Aug, 2013
(11 years ago)
Expired
US5362755 Method for treating asthma using optically pure (R)-albuterol 25 Mar, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xopenex's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Hikma News

Accusations of Delaying Release of Generic Sleep Disorder Drug Hurled at Jazz and Hikma to Keep Prices High

28 Aug, 2024

Legal action required for Jazz and Hikma to address allegations of 'reverse payment' related to narcolepsy medication - XM

27 Aug, 2024

Jazz Pharmaceuticals and Hikma Pharmaceuticals to address allegations of 'reverse payment' concerning narcolepsy medication - Westlaw Today

27 Aug, 2024

Federal Circuit revives lawsuit alleging infringement of narrow label - BioWorld

27 Jun, 2024

See More